Which patients should switch from rituximab to obinutuzumab in refractory nephrotic syndrome?

Study limitation reported by the research below: “This is a letter to the editor, not a primary research study; the n=92 cohort data cited are from a previously published single-center study (Fujinaga 2021), not newly reported here.”